Fortress Biotech Inc.

08/28/2020 | Press release | Distributed by Public on 08/28/2020 06:34

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease